tirzepatide efficacy and Safety of in Adults with Obesity or Overweight Published July 21, 2022 N Engl J Med 2022;387:205–216 🔹 Background Obesity and overweight remain major global health problems associated with Starting tirzepatide earlier in #Type2Diabetes

Maintaining Your Results After Treatment Transitioning Off GLP-1 Medications Deciding when and how to stop GLP-1 therapy requires careful planning with your healthcare provider

See additional terms and conditions for Chegg Study or Chegg Study Pack on Chegg.com Show transcribed image text Question: 2

For patients who experience severe "histamine dumps" at night, which can cause insomnia, sudden tachycardia, or night sweats, taking the dose in the late afternoon or early evening may provide targeted mast cell stabilization during the most vulnerable hours

Addressing these challenges requires systemic reform of the patent system, expanded insurance coverage, and a commitment to equitable access